Article(id=1325223547567748037, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1325223510582370941, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2026.07.017, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1768924800000, receivedDateStr=2026-01-21, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1793887515202, onlineDateStr=2026-11-05, pubDate=1783612800000, pubDateStr=2026-07-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793887515202, onlineIssueDateStr=2026-11-05, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793887515202, creator=13701087609, updateTime=1793887515202, updator=13701087609, issue=Issue{id=1325223510582370941, tenantId=1146029695717560320, journalId=1319690329412173987, year='2026', volume='47', issue='7', pageStart='709', pageEnd='830', issueExtLink='null', onlineDate='null', pubDate='1783612800000', pubDateStr='2026-07-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1793887506384, creator='13701087609', updateTime=1793934747763, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1325421655350194807, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1325223510582370941, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1325421655350194808, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1325223510582370941, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=818, endPage=824, ext={EN=ArticleExt(id=1325223547819406278, articleId=1325223547567748037, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress on the treatment of human epidermal growth factor receptor 2 positive breast cancer with traditional Chinese medicine combined with targeted drugs, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Human epidermal growth factor receptor(HER)2 positive breast cancer is a specific type of breast cancer that typically has a higher invasiveness and poorer prognosis. Targeted drugs such as trastuzumab and pertuzumab can specifically bind to HER2 receptors, inhibit the growth and spread of cancer cells, and prolong the survival of patients.traditional Chinese medicine(TCM), as a precious treasure of the nation, having accumulated rich experience in the treatment of breast cancer. It could enhance clinical treatment outcomes, reduce adverse reactions, improve patients'immune function, serve as an important complementary approach to breast cancer treatment. The combination of targeted drugs with TCM has achieved good results in the treatment of HER2 positive breast cancer. Based on the current situation of traditional Chinese medicine combined with targeted drugs in the treatment of HER2 positive breast cancer, this paper analyzed and summarized existing studies to provide a reference for comprehensive clinical treatment of breast cancer..

, authors=Qingxiu SUN1, Fenghua PU2, *, authorsList=Qingxiu SUN, Fenghua PU, authorCompany=null, correspAuthors=Fenghua PU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1325223548041704391, articleId=1325223547567748037, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=中医药联合靶向药物治疗人表皮生长因子受体2阳性乳腺癌研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

人表皮生长因子受体(human epidermal growth factor receptor,HER)2阳性乳腺癌是一种特定类型的乳腺癌,通常具有较高的侵袭性,预后较差。靶向药物如曲妥珠单抗及帕妥珠单抗等能特异性结合HER2受体,抑制肿瘤细胞的生长及扩散,延长患者生存期。中医药作为民族瑰宝,在乳腺癌治疗方面积累了丰富经验,能提高临床疗效,减少不良反应,提高患者免疫功能,成为乳腺癌临床治疗的重要补充手段。将靶向药物与中医药联合治疗HER2阳性乳腺癌取得较好效果。该文基于中医药联合靶向药物治疗HER2阳性乳腺癌现状,对已有研究进行分析和总结,为HER2阳性乳腺癌患者的临床综合治疗提供参考。

, authors=孙清秀1, 蒲凤华2, *, authorsList=孙清秀, 蒲凤华, authorCompany=null, correspAuthors=蒲凤华, authorNote=

孙清秀,药师,研究方向:处方审核及药品养护工作。

, correspAuthorsNote=
蒲凤华,主管药师,研究方向:处方审核及药品养护工作。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=6/4mosnteUjF7sT0huRnFQ==, magXml=sE64fUcZcHMj57X2MqOS1Q==, pdfUrl=null, pdf=C7AHXvz34FaBo9Qbb9laSg==, pdfFileSize=996972, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=UwbG7lBA6AROHkCk7uGZfQ==, mapNumber=null, fund=null)}, authors=[Author(id=1325223549614568400, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325223549740397522, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, authorId=1325223549614568400, language=EN, stringName=Qingxiu SUN, firstName=Qingxiu, middleName=null, lastName=SUN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325223549824283603, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, authorId=1325223549614568400, language=CN, stringName=孙清秀, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.川北医学院附属医院药剂科,四川 南充 637000, bio={"content":"

孙清秀,药师,研究方向:处方审核及药品养护工作。

"}, bioImg=null, bioContent=

孙清秀,药师,研究方向:处方审核及药品养护工作。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325223548226253768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, xref=1., ext=[AuthorCompanyExt(id=1325223548234642377, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, companyId=1325223548226253768, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China), AuthorCompanyExt(id=1325223548243030986, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, companyId=1325223548226253768, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.川北医学院附属医院药剂科,四川 南充 637000)])]), Author(id=1325223549929141205, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1325223550046581719, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, authorId=1325223549929141205, language=EN, stringName=Fenghua PU, firstName=Fenghua, middleName=null, lastName=PU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Pharmacy, Southern County People's Hospital, Nanchong 637300, Sichuan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325223550134662104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, authorId=1325223549929141205, language=CN, stringName=蒲凤华, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.南部县人民医院药剂科,四川 南充 637300, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325223549492933580, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, xref=2., ext=[AuthorCompanyExt(id=1325223549501322189, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, companyId=1325223549492933580, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Southern County People's Hospital, Nanchong 637300, Sichuan Province, China), AuthorCompanyExt(id=1325223549509710798, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, companyId=1325223549492933580, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.南部县人民医院药剂科,四川 南充 637300)])])], keywords=[Keyword(id=1325223550239519705, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, language=EN, orderNo=1, keyword=breast cancer), Keyword(id=1325223550335988698, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, language=EN, orderNo=2, keyword=traditional Chinese medicine), Keyword(id=1325223550419874779, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, language=EN, orderNo=3, keyword=targeted therapy), Keyword(id=1325223550495372252, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, language=EN, orderNo=4, keyword=reverse drug resistance), Keyword(id=1325223550575064029, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, language=EN, orderNo=5, keyword=enhance therapeutic efficacy), Keyword(id=1325223550658950110, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, language=CN, orderNo=1, keyword=乳腺癌), Keyword(id=1325223550738641887, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, language=CN, orderNo=2, keyword=中医药), Keyword(id=1325223550826722272, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, language=CN, orderNo=3, keyword=靶向治疗), Keyword(id=1325223550902219745, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, language=CN, orderNo=4, keyword=逆转耐药), Keyword(id=1325223550973522914, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, language=CN, orderNo=5, keyword=增强疗效)], refs=[Reference(id=1325223551078380515, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263., articleTitle=null, refAbstract=null), Reference(id=1325223551153877988, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3):221-231., articleTitle=null, refAbstract=null), Reference(id=1325223551250346981, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Gion M, Trapani D, Cortes A, et al. Systemic therapy for HER2-positive metastatic breast cancer:moving into a new era[J]. Am Soc Clin Oncol Educ Book, 2022, 42:1-11., articleTitle=null, refAbstract=null), Reference(id=1325223551346815974, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=罗师萍, 张捷, 俞育帅, 等. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8):876-886., articleTitle=null, refAbstract=null), Reference(id=1325223551430702055, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=姜明霞, 李俏, 徐兵河. HER2阳性晚期乳腺癌靶向治疗药物分类及临床研究进展[J]. 中国肿瘤, 2024, 33(7):583-595., articleTitle=null, refAbstract=null), Reference(id=1325223551514588136, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Swain S M, Miles D, Kim S B, et al. Pertuzumab,trastuzumab, and docetaxel for HER2-positive metastatic breast cancer(CLEOPATRA):end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(4):519-530., articleTitle=null, refAbstract=null), Reference(id=1325223551594279913, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Andre F, Hee Park Y, Kim S B, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer(DESTINY-Breast02):a randomised, open-label, multicentre, phase 3 trial[J]. Lancet,2023, 401(10390):1773-1785., articleTitle=null, refAbstract=null), Reference(id=1325223551661388778, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Stanowicka-Grada M, Senkus E. Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer[J]. Curr Treat Options Oncol, 2023, 24(11):1633-1650., articleTitle=null, refAbstract=null), Reference(id=1325223551736886251, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Yan M, Bian L, Hu X C, et al. Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes(PHENIX):a randomized, double-blind, placebo-controlled phase 3 study[J]. Transl Breast Cancer Res, 2020, 1:13., articleTitle=null, refAbstract=null), Reference(id=1325223551820772332, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Bonotto M, de Pieri G, Esposto R, et al. Antibody-drug conjugates in elderly patients with breast cancer[J]. Breast,2025, 80:104428., articleTitle=null, refAbstract=null), Reference(id=1325223551913047021, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=方宇航, 谢伊, 刘苏颖, 等. 中药汤剂联合曲妥珠单抗治疗HER-2阳性乳腺癌临床疗效的meta分析[J]. 中国医院用药评价与分析, 2023, 23(9):1114-1118., articleTitle=null, refAbstract=null), Reference(id=1325223552005321710, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=赵美凤, 吴丽荣, 苏丽婷, 等. 香菇多糖联合曲妥珠单抗治疗HER-2阳性晚期乳腺癌患者的疗效及对肝功能的影响[J]. 北方药学, 2023, 20(5):132-134., articleTitle=null, refAbstract=null), Reference(id=1325223552110179311, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=牟微娜, 邵琰, 李肖亮. 西黄胶囊联合曲妥珠单抗治疗表皮生长因子受体2阳性晚期乳腺癌临床研究[J]. 新中医,2023, 55(3):163-167., articleTitle=null, refAbstract=null), Reference(id=1325223552202454000, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=张至惠, 胡述博, 王志峰, 等. 补肾活血汤联合曲妥珠单抗治疗HER-2阳性晚期乳腺癌临床疗效及对患者免疫功能的影响[J]. 世界中医药, 2019, 14(4):993-996., articleTitle=null, refAbstract=null), Reference(id=1325223552290534385, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=黄芬. 榄香烯注射液联合曲妥珠单抗治疗局部晚期乳腺癌的临床研究[J]. 现代药物与临床, 2018, 33(6):1453-1456., articleTitle=null, refAbstract=null), Reference(id=1325223552395391986, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=周静, 范震宇, 倪华, 等. 曲妥珠单抗联合榄香烯注射液治疗乳腺癌的疗效及对血清BNP、cTnⅠ表达的影响[J]. 现代生物医学进展, 2022, 22(9):1770-1774., articleTitle=null, refAbstract=null), Reference(id=1325223552517026803, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=张林, 邓钰, 张可良, 等. 复方苦参注射液联合曲妥珠单抗治疗HER-2阳性中晚期乳腺癌临床观察[J]. 山西中医,2023, 39(10):38-39., articleTitle=null, refAbstract=null), Reference(id=1325223552617690100, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=郭田田. 复方苦参注射液联合TCbHP化疗方案治疗HER-2阳性乳腺癌疗效及安全性[J]. 药品评价, 2024, 21(1):63-67., articleTitle=null, refAbstract=null), Reference(id=1325223552722547701, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=秦海运, 潘淑云, 李政, 等. 复方苦参注射液联合拉帕替尼治疗HER-2阳性晚期乳腺癌疗效及对肿瘤标志物的影响[J]. 世界中医药, 2018, 13(6):1472-1476., articleTitle=null, refAbstract=null), Reference(id=1325223552831599606, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=刘兆捷, 党安建, 郭静. 含曲妥珠单抗化疗方案联合参芪扶正注射液治疗HER2阳性乳腺癌的效果[J]. 临床医学,2025, 45(1):105-107., articleTitle=null, refAbstract=null), Reference(id=1325223552928068599, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=谭何浪, 邓晓琴, 李召红, 等. 六味地黄汤联合多西他赛和卡培他滨及曲妥珠单抗治疗乳腺癌的临床疗效及安全性研究[J]. 内蒙古中医药, 2021, 40(11):33-34., articleTitle=null, refAbstract=null), Reference(id=1325223553020343288, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=艾宝銮. 曲妥珠单抗联合花青素治疗150例曲妥珠单抗耐药乳腺癌患者的临床疗效评价[J]. 世界复合医学, 2019,5(6):93-95., articleTitle=null, refAbstract=null), Reference(id=1325223553095840761, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=胡尔维, 喻腾云, 张雨露, 等. 槐耳颗粒联合曲妥珠单抗及帕妥珠单抗治疗HER-2阳性乳腺癌的临床效果[J]. 临床合理用药, 2025, 18(27):19-21., articleTitle=null, refAbstract=null), Reference(id=1325223553192309754, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=孙亚飞, 王振, 何苗. 扶正益气方联合曲妥珠单抗治疗HER-2阳性乳腺癌临床研究[J]. 新中医, 2023, 55(11):160-163, articleTitle=null, refAbstract=null), Reference(id=1325223553276195835, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=赵亚娟, 毕彦智, 李月红, 等. 培元抗癌汤结合曲妥珠单抗对乳腺癌患者临床疗效、肿瘤标志物影响研究[J].辽宁中医杂志, 2022, 49(2):97-100., articleTitle=null, refAbstract=null), Reference(id=1325223553360081916, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=顾文静. 通阳祛瘀中药联合曲妥珠单抗治疗乳腺癌疗效及对血清CEA、CA153、CA724的影响[J]. 现代中西医结合杂志, 2017, 26(23):2599-2601., articleTitle=null, refAbstract=null), Reference(id=1325223553431385085, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=钟利敏, 俞丹, 郑恺. 扶正消瘤方联合药物靶向治疗HER-2阳性复发转移性乳腺癌临床观察[J]. 浙江中西医结合杂志, 2019, 29(11):917-920., articleTitle=null, refAbstract=null), Reference(id=1325223553536242686, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=彭喜娜, 白倩, 皇甫乐双. 泽漆扶正散结汤联合帕妥珠单抗、曲妥珠单抗治疗HER2阳性乳腺癌的临床效果[J]. 河南医学研究, 2025, 34(13):2444-2448., articleTitle=null, refAbstract=null), Reference(id=1325223553645294591, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=周丽, 陈友国, 黄定良, 等. 芪胶升白胶囊对曲妥珠单抗和多西紫杉醇治疗转移性乳腺癌的影响[J]. 中国现代医生,2020, 58(4):149-152., articleTitle=null, refAbstract=null), Reference(id=1325223553729180672, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=张洋, 刘晓菲, 朱晴, 等. 加味生脉饮对HER-2阳性乳腺癌赫赛汀所致心脏毒性防治作用研究[J]. 现代中西医结合杂志, 2020, 29(24):2640-2643., articleTitle=null, refAbstract=null), Reference(id=1325223553855008768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=李伟君. 研究补肾活血汤联合曲妥珠单抗治疗人表皮生长因子受体2(HER-2)阳性晚期乳腺癌(肝肾阴虚型)临床疗效及对患者免疫功能的影响[J]. 临床医药文献电子杂志,2019, 6(71):56., articleTitle=null, refAbstract=null), Reference(id=1325223553938894849, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=周芹芹, 林芬, 钟小娟, 等. 黄芪多糖在HER-2阳性乳腺癌患者化疗中增效减毒的作用及其对血清HER-2-ECD、TAP和疗效的影响[J]. 中国医学创新, 2024, 21(20):57-62., articleTitle=null, refAbstract=null), Reference(id=1325223554026975234, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=赖靖江. 参苓白术散治疗HER2靶向药物吡咯替尼所致腹泻的作用及机制研究[D]. 济南:山东中医药大学, 2023., articleTitle=null, refAbstract=null), Reference(id=1325223554119249923, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=肖莘柒, 田甜, 张维, 等. 复方生脉饮预防HER-2阳性乳腺癌患者肿瘤治疗相关心功能不全的疗效[J]. 现代肿瘤医学,2026, 34(3):393-401., articleTitle=null, refAbstract=null), Reference(id=1325223554219913220, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=王磊, 李有怀, 唐铁雷, 等. 扶正消瘤汤联合曲妥珠单抗治疗HER-2阳性晚期乳腺癌临床疗效及对血清肿瘤标志物水平的影响[J]. 四川中医, 2019, 37(2):170-173., articleTitle=null, refAbstract=null), Reference(id=1325223554295410694, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=雷碧黠, 张梦瑶, 陈晓锐, 等. 表没食子儿茶素没食子酸酯联合曲妥珠单抗对HER2过表达乳腺癌细胞增殖的影响及其机制[J]. 药学实践杂志, 2022, 40(2):136-142., articleTitle=null, refAbstract=null), Reference(id=1325223554429628423, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=张梦瑶, 雷碧黠, 解伟, 等. 芹菜素与曲妥珠单抗联用对HER2阳性乳腺癌协同抗肿瘤作用[J]. 中华肿瘤防治杂志,2024, 31(7):405-413., articleTitle=null, refAbstract=null), Reference(id=1325223554526097416, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang L Y, Liu Q J, Huang L, et al. Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway[J]. Biochem Biophys Res Commun, 2020, 531(3):364-371., articleTitle=null, refAbstract=null), Reference(id=1325223554622566409, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Tian Z Y, Yang Y, Wu H, et al. The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers[J]. Heliyon, 2022, 8(8):e10410., articleTitle=null, refAbstract=null), Reference(id=1325223554714841098, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=饶应颖, 李恒宇. 青藤碱用于乳腺癌治疗的机制研究进展[J]. 世界临床药物, 2024, 45(9):986-990., articleTitle=null, refAbstract=null), Reference(id=1325223554798727179, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Li F F, Wu Y Y, Shi Y Y, et al. Xianling Lianxia formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer[J]. Acta Biochim Biophys Sin(Shanghai), 2024, 56(3):462-473., articleTitle=null, refAbstract=null), Reference(id=1325223554920361996, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Li F F, Shi Y Y, Ma M, et al. Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC[J]. J Pharm Anal,2024, 14(10):100977., articleTitle=null, refAbstract=null), Reference(id=1325223555012636685, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang R H, Qiao H Y, Chen S N, et al. Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS[J]. Cancer Biol Ther, 2016,17(9):925-934., articleTitle=null, refAbstract=null), Reference(id=1325223555109105678, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=杨芳, 沈国栋, 徐婷娟, 等. 石蒜碱调节AKT/mTOR信号通路对乳腺癌细胞曲妥珠单抗耐药的影响[J]. 南开大学学报(自然科学版), 2024, 57(4):79-85., articleTitle=null, refAbstract=null), Reference(id=1325223555184603151, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=李斐斐, 史有阳, 杨小娟, 等. 从“卫气留之”探究仙苓莲夏方增强NK细胞活性改善HER2阳性乳腺癌曲妥珠单抗耐药的机制[J]. 中华中医药杂志, 2023, 38(5):2371-2377., articleTitle=null, refAbstract=null), Reference(id=1325223555285266448, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=赵子伟, 姚永强. 吡咯替尼联合槐耳颗粒治疗人表皮生长因子受体2阳性晚期乳腺癌患者化疗耐药效果观察[J]. 临床军医杂志, 2020, 48(3):284-286., articleTitle=null, refAbstract=null), Reference(id=1325223555394318353, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=陈超英, 刘灵芝, 朱一喜, 等. 网络药理学及实验验证探究紫草有效成分紫草素调控HER2阳性乳腺癌耐药的药理机制[J]. 肿瘤药学, 2026, 16(2):75-82., articleTitle=null, refAbstract=null), Reference(id=1325223555515953170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=谷焕鹏, 胡升芳, 凌云, 等. 解毒化浊方含药血清调控TANs对HER-2阳性乳腺癌肿瘤微环境的影响[J]. 时珍国医国药, 2023, 34(2):299-302., articleTitle=null, refAbstract=null), Reference(id=1325223555612422163, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=李佳佳, 边静, 张彭辉, 等. 贞芪扶正颗粒联合曲帕双靶治疗HER2阳性乳腺癌临床评价[J]. 中国药物应用与监测,2025, 22(6):1147-1150., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1325223548226253768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, xref=1., ext=[AuthorCompanyExt(id=1325223548234642377, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, companyId=1325223548226253768, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China), AuthorCompanyExt(id=1325223548243030986, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, companyId=1325223548226253768, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.川北医学院附属医院药剂科,四川 南充 637000)]), AuthorCompany(id=1325223549492933580, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, xref=2., ext=[AuthorCompanyExt(id=1325223549501322189, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, companyId=1325223549492933580, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Southern County People's Hospital, Nanchong 637300, Sichuan Province, China), AuthorCompanyExt(id=1325223549509710798, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, companyId=1325223549492933580, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.南部县人民医院药剂科,四川 南充 637300)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2026.07.017, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.07.017, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2026.07.017, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2026.07.017, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1783612800000, fullTextJson=null, articleText=null, reference=null)
收藏切换
中医药联合靶向药物治疗人表皮生长因子受体2阳性乳腺癌研究进展
孙清秀 1 , 蒲凤华 2, *
世界临床药物 | 综述评论 2026,47(7): 818-824
收起
收藏切换
世界临床药物 |综述评论 2026 , 47 (7) : 818 -824
中医药联合靶向药物治疗人表皮生长因子受体2阳性乳腺癌研究进展
全屏
[Author(id=1325223549614568400, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1325223549740397522, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, authorId=1325223549614568400, language=EN, stringName=Qingxiu SUN, firstName=Qingxiu, middleName=null, lastName=SUN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325223549824283603, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, authorId=1325223549614568400, language=CN, stringName=孙清秀, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.川北医学院附属医院药剂科,四川 南充 637000, bio={"content":"

孙清秀,药师,研究方向:处方审核及药品养护工作。

"}, bioImg=null, bioContent=

孙清秀,药师,研究方向:处方审核及药品养护工作。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325223548226253768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, xref=1., ext=[AuthorCompanyExt(id=1325223548234642377, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, companyId=1325223548226253768, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China), AuthorCompanyExt(id=1325223548243030986, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, companyId=1325223548226253768, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.川北医学院附属医院药剂科,四川 南充 637000)])]), Author(id=1325223549929141205, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1325223550046581719, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, authorId=1325223549929141205, language=EN, stringName=Fenghua PU, firstName=Fenghua, middleName=null, lastName=PU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Pharmacy, Southern County People's Hospital, Nanchong 637300, Sichuan Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1325223550134662104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, authorId=1325223549929141205, language=CN, stringName=蒲凤华, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.南部县人民医院药剂科,四川 南充 637300, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1325223549492933580, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, xref=2., ext=[AuthorCompanyExt(id=1325223549501322189, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, companyId=1325223549492933580, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Pharmacy, Southern County People's Hospital, Nanchong 637300, Sichuan Province, China), AuthorCompanyExt(id=1325223549509710798, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1325223547567748037, companyId=1325223549492933580, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.南部县人民医院药剂科,四川 南充 637300)])])]
孙清秀1, 蒲凤华2, *
作者信息
  • 1.川北医学院附属医院药剂科,四川 南充 637000
  • 2.南部县人民医院药剂科,四川 南充 637300
通讯作者:
蒲凤华,主管药师,研究方向:处方审核及药品养护工作。
作者简介:

孙清秀,药师,研究方向:处方审核及药品养护工作。

Research progress on the treatment of human epidermal growth factor receptor 2 positive breast cancer with traditional Chinese medicine combined with targeted drugs
Qingxiu SUN1, Fenghua PU2, *
Affiliations
  • 1.Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
  • 2.Department of Pharmacy, Southern County People's Hospital, Nanchong 637300, Sichuan Province, China
出版时间: 2026-07-10 doi: 10.13683/j.wph.2026.07.017
文章导航
收藏切换

人表皮生长因子受体(human epidermal growth factor receptor,HER)2阳性乳腺癌是一种特定类型的乳腺癌,通常具有较高的侵袭性,预后较差。靶向药物如曲妥珠单抗及帕妥珠单抗等能特异性结合HER2受体,抑制肿瘤细胞的生长及扩散,延长患者生存期。中医药作为民族瑰宝,在乳腺癌治疗方面积累了丰富经验,能提高临床疗效,减少不良反应,提高患者免疫功能,成为乳腺癌临床治疗的重要补充手段。将靶向药物与中医药联合治疗HER2阳性乳腺癌取得较好效果。该文基于中医药联合靶向药物治疗HER2阳性乳腺癌现状,对已有研究进行分析和总结,为HER2阳性乳腺癌患者的临床综合治疗提供参考。

乳腺癌  /  中医药  /  靶向治疗  /  逆转耐药  /  增强疗效

Human epidermal growth factor receptor(HER)2 positive breast cancer is a specific type of breast cancer that typically has a higher invasiveness and poorer prognosis. Targeted drugs such as trastuzumab and pertuzumab can specifically bind to HER2 receptors, inhibit the growth and spread of cancer cells, and prolong the survival of patients.traditional Chinese medicine(TCM), as a precious treasure of the nation, having accumulated rich experience in the treatment of breast cancer. It could enhance clinical treatment outcomes, reduce adverse reactions, improve patients'immune function, serve as an important complementary approach to breast cancer treatment. The combination of targeted drugs with TCM has achieved good results in the treatment of HER2 positive breast cancer. Based on the current situation of traditional Chinese medicine combined with targeted drugs in the treatment of HER2 positive breast cancer, this paper analyzed and summarized existing studies to provide a reference for comprehensive clinical treatment of breast cancer..

breast cancer  /  traditional Chinese medicine  /  targeted therapy  /  reverse drug resistance  /  enhance therapeutic efficacy
孙清秀, 蒲凤华. 中医药联合靶向药物治疗人表皮生长因子受体2阳性乳腺癌研究进展. 世界临床药物, 2026 , 47 (7) : 818 -824 . DOI: 10.13683/j.wph.2026.07.017
Qingxiu SUN, Fenghua PU. Research progress on the treatment of human epidermal growth factor receptor 2 positive breast cancer with traditional Chinese medicine combined with targeted drugs[J]. World Clinical Drug, 2026 , 47 (7) : 818 -824 . DOI: 10.13683/j.wph.2026.07.017

参考文献 引证文献
排序方式:
[1]
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.
[2]
郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3):221-231.
[3]
Gion M, Trapani D, Cortes A, et al. Systemic therapy for HER2-positive metastatic breast cancer:moving into a new era[J]. Am Soc Clin Oncol Educ Book, 2022, 42:1-11.
[4]
罗师萍, 张捷, 俞育帅, 等. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8):876-886.
[5]
姜明霞, 李俏, 徐兵河. HER2阳性晚期乳腺癌靶向治疗药物分类及临床研究进展[J]. 中国肿瘤, 2024, 33(7):583-595.
[6]
Swain S M, Miles D, Kim S B, et al. Pertuzumab,trastuzumab, and docetaxel for HER2-positive metastatic breast cancer(CLEOPATRA):end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(4):519-530.
[7]
Andre F, Hee Park Y, Kim S B, et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer(DESTINY-Breast02):a randomised, open-label, multicentre, phase 3 trial[J]. Lancet,2023, 401(10390):1773-1785.
[8]
Stanowicka-Grada M, Senkus E. Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer[J]. Curr Treat Options Oncol, 2023, 24(11):1633-1650.
[9]
Yan M, Bian L, Hu X C, et al. Pyrotinib plus capecitabine for human epidermal factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes(PHENIX):a randomized, double-blind, placebo-controlled phase 3 study[J]. Transl Breast Cancer Res, 2020, 1:13.
[10]
Bonotto M, de Pieri G, Esposto R, et al. Antibody-drug conjugates in elderly patients with breast cancer[J]. Breast,2025, 80:104428.
[11]
方宇航, 谢伊, 刘苏颖, 等. 中药汤剂联合曲妥珠单抗治疗HER-2阳性乳腺癌临床疗效的meta分析[J]. 中国医院用药评价与分析, 2023, 23(9):1114-1118.
[12]
赵美凤, 吴丽荣, 苏丽婷, 等. 香菇多糖联合曲妥珠单抗治疗HER-2阳性晚期乳腺癌患者的疗效及对肝功能的影响[J]. 北方药学, 2023, 20(5):132-134.
[13]
牟微娜, 邵琰, 李肖亮. 西黄胶囊联合曲妥珠单抗治疗表皮生长因子受体2阳性晚期乳腺癌临床研究[J]. 新中医,2023, 55(3):163-167.
[14]
张至惠, 胡述博, 王志峰, 等. 补肾活血汤联合曲妥珠单抗治疗HER-2阳性晚期乳腺癌临床疗效及对患者免疫功能的影响[J]. 世界中医药, 2019, 14(4):993-996.
[15]
黄芬. 榄香烯注射液联合曲妥珠单抗治疗局部晚期乳腺癌的临床研究[J]. 现代药物与临床, 2018, 33(6):1453-1456.
[16]
周静, 范震宇, 倪华, 等. 曲妥珠单抗联合榄香烯注射液治疗乳腺癌的疗效及对血清BNP、cTnⅠ表达的影响[J]. 现代生物医学进展, 2022, 22(9):1770-1774.
[17]
张林, 邓钰, 张可良, 等. 复方苦参注射液联合曲妥珠单抗治疗HER-2阳性中晚期乳腺癌临床观察[J]. 山西中医,2023, 39(10):38-39.
[18]
郭田田. 复方苦参注射液联合TCbHP化疗方案治疗HER-2阳性乳腺癌疗效及安全性[J]. 药品评价, 2024, 21(1):63-67.
[19]
秦海运, 潘淑云, 李政, 等. 复方苦参注射液联合拉帕替尼治疗HER-2阳性晚期乳腺癌疗效及对肿瘤标志物的影响[J]. 世界中医药, 2018, 13(6):1472-1476.
[20]
刘兆捷, 党安建, 郭静. 含曲妥珠单抗化疗方案联合参芪扶正注射液治疗HER2阳性乳腺癌的效果[J]. 临床医学,2025, 45(1):105-107.
[21]
谭何浪, 邓晓琴, 李召红, 等. 六味地黄汤联合多西他赛和卡培他滨及曲妥珠单抗治疗乳腺癌的临床疗效及安全性研究[J]. 内蒙古中医药, 2021, 40(11):33-34.
[22]
艾宝銮. 曲妥珠单抗联合花青素治疗150例曲妥珠单抗耐药乳腺癌患者的临床疗效评价[J]. 世界复合医学, 2019,5(6):93-95.
[23]
胡尔维, 喻腾云, 张雨露, 等. 槐耳颗粒联合曲妥珠单抗及帕妥珠单抗治疗HER-2阳性乳腺癌的临床效果[J]. 临床合理用药, 2025, 18(27):19-21.
[24]
孙亚飞, 王振, 何苗. 扶正益气方联合曲妥珠单抗治疗HER-2阳性乳腺癌临床研究[J]. 新中医, 2023, 55(11):160-163
[25]
赵亚娟, 毕彦智, 李月红, 等. 培元抗癌汤结合曲妥珠单抗对乳腺癌患者临床疗效、肿瘤标志物影响研究[J].辽宁中医杂志, 2022, 49(2):97-100.
[26]
顾文静. 通阳祛瘀中药联合曲妥珠单抗治疗乳腺癌疗效及对血清CEA、CA153、CA724的影响[J]. 现代中西医结合杂志, 2017, 26(23):2599-2601.
[27]
钟利敏, 俞丹, 郑恺. 扶正消瘤方联合药物靶向治疗HER-2阳性复发转移性乳腺癌临床观察[J]. 浙江中西医结合杂志, 2019, 29(11):917-920.
[28]
彭喜娜, 白倩, 皇甫乐双. 泽漆扶正散结汤联合帕妥珠单抗、曲妥珠单抗治疗HER2阳性乳腺癌的临床效果[J]. 河南医学研究, 2025, 34(13):2444-2448.
[29]
周丽, 陈友国, 黄定良, 等. 芪胶升白胶囊对曲妥珠单抗和多西紫杉醇治疗转移性乳腺癌的影响[J]. 中国现代医生,2020, 58(4):149-152.
[30]
张洋, 刘晓菲, 朱晴, 等. 加味生脉饮对HER-2阳性乳腺癌赫赛汀所致心脏毒性防治作用研究[J]. 现代中西医结合杂志, 2020, 29(24):2640-2643.
[31]
李伟君. 研究补肾活血汤联合曲妥珠单抗治疗人表皮生长因子受体2(HER-2)阳性晚期乳腺癌(肝肾阴虚型)临床疗效及对患者免疫功能的影响[J]. 临床医药文献电子杂志,2019, 6(71):56.
[32]
周芹芹, 林芬, 钟小娟, 等. 黄芪多糖在HER-2阳性乳腺癌患者化疗中增效减毒的作用及其对血清HER-2-ECD、TAP和疗效的影响[J]. 中国医学创新, 2024, 21(20):57-62.
[33]
赖靖江. 参苓白术散治疗HER2靶向药物吡咯替尼所致腹泻的作用及机制研究[D]. 济南:山东中医药大学, 2023.
[34]
肖莘柒, 田甜, 张维, 等. 复方生脉饮预防HER-2阳性乳腺癌患者肿瘤治疗相关心功能不全的疗效[J]. 现代肿瘤医学,2026, 34(3):393-401.
[35]
王磊, 李有怀, 唐铁雷, 等. 扶正消瘤汤联合曲妥珠单抗治疗HER-2阳性晚期乳腺癌临床疗效及对血清肿瘤标志物水平的影响[J]. 四川中医, 2019, 37(2):170-173.
[36]
雷碧黠, 张梦瑶, 陈晓锐, 等. 表没食子儿茶素没食子酸酯联合曲妥珠单抗对HER2过表达乳腺癌细胞增殖的影响及其机制[J]. 药学实践杂志, 2022, 40(2):136-142.
[37]
张梦瑶, 雷碧黠, 解伟, 等. 芹菜素与曲妥珠单抗联用对HER2阳性乳腺癌协同抗肿瘤作用[J]. 中华肿瘤防治杂志,2024, 31(7):405-413.
[38]
Zhang L Y, Liu Q J, Huang L, et al. Combination of lapatinib and luteolin enhances the therapeutic efficacy of lapatinib on human breast cancer through the FOXO3a/NQO1 pathway[J]. Biochem Biophys Res Commun, 2020, 531(3):364-371.
[39]
Tian Z Y, Yang Y, Wu H, et al. The Nrf2 inhibitor brusatol synergistically enhances the cytotoxic effect of lapatinib in HER2-positive cancers[J]. Heliyon, 2022, 8(8):e10410.
[40]
饶应颖, 李恒宇. 青藤碱用于乳腺癌治疗的机制研究进展[J]. 世界临床药物, 2024, 45(9):986-990.
[41]
Li F F, Wu Y Y, Shi Y Y, et al. Xianling Lianxia formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer[J]. Acta Biochim Biophys Sin(Shanghai), 2024, 56(3):462-473.
[42]
Li F F, Shi Y Y, Ma M, et al. Xianling Lianxia formula improves the efficacy of trastuzumab by enhancing NK cell-mediated ADCC in HER2-positive BC[J]. J Pharm Anal,2024, 14(10):100977.
[43]
Zhang R H, Qiao H Y, Chen S N, et al. Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS[J]. Cancer Biol Ther, 2016,17(9):925-934.
[44]
杨芳, 沈国栋, 徐婷娟, 等. 石蒜碱调节AKT/mTOR信号通路对乳腺癌细胞曲妥珠单抗耐药的影响[J]. 南开大学学报(自然科学版), 2024, 57(4):79-85.
[45]
李斐斐, 史有阳, 杨小娟, 等. 从“卫气留之”探究仙苓莲夏方增强NK细胞活性改善HER2阳性乳腺癌曲妥珠单抗耐药的机制[J]. 中华中医药杂志, 2023, 38(5):2371-2377.
[46]
赵子伟, 姚永强. 吡咯替尼联合槐耳颗粒治疗人表皮生长因子受体2阳性晚期乳腺癌患者化疗耐药效果观察[J]. 临床军医杂志, 2020, 48(3):284-286.
[47]
陈超英, 刘灵芝, 朱一喜, 等. 网络药理学及实验验证探究紫草有效成分紫草素调控HER2阳性乳腺癌耐药的药理机制[J]. 肿瘤药学, 2026, 16(2):75-82.
[48]
谷焕鹏, 胡升芳, 凌云, 等. 解毒化浊方含药血清调控TANs对HER-2阳性乳腺癌肿瘤微环境的影响[J]. 时珍国医国药, 2023, 34(2):299-302.
[49]
李佳佳, 边静, 张彭辉, 等. 贞芪扶正颗粒联合曲帕双靶治疗HER2阳性乳腺癌临床评价[J]. 中国药物应用与监测,2025, 22(6):1147-1150.
2026年第47卷第7期
53
9
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2026.07.017
  • 接收时间:2026-01-21
  • 首发时间:2026-11-05
  • 出版时间:2026-07-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2026-01-21
基金
作者信息
    1.川北医学院附属医院药剂科,四川 南充 637000
    2.南部县人民医院药剂科,四川 南充 637300

通讯作者:

蒲凤华,主管药师,研究方向:处方审核及药品养护工作。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2026.07.017
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏